Australia's most trusted
source of pharma news
Posted 22 August 2025 AM
MSAC may have foreshadowed the PBAC’s decision on two medicines – Gilead’s Hepcludex and Taiho Pharma’s Lytgobi - considered at the July meeting, with outcomes to be released this afternoon.
After considering a second codependent submission in April 2025 MSAC has supported the creation of a new MBS item for the quantitation of hepatitis D viral RNA using PCR testing to determine eligibility for treatment with Hepcludex and monitor the efficacy of Hepcludex in patients with chronic HDV infection with compensated liver disease.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.